1 / 73

approach to DM

Classification,pathogenesis,causes,diagnosis and treatment

30947
Download Presentation

approach to DM

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Approach to DM Professor/ Mohammed Ahmed Bamashmos Professor of internal medicine and endocrinology Faculty of medicine Sanaa University

  2. Defination Diabetes is a group of metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both. The chronic hyperglycemia of diabetes is associated with long-term damage, dysfunction, and failure of differentorgans, especially the eyes, kidneys, nerves, heart, and blood vessels.The degree of hyperglycemia (if any) may change over time, depending on the extent of the underlying disease process .A disease process may be present but may not have progressed far enough to cause hyperglycemia. The same disease process can cause impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) without fulfilling the criteria for the diagnosis of diabetes. In some individuals with diabetes, adequate glycemic control can be achieved with weight reduction, exercise, and/or oral glucose-lowering agents. These individuals therefore do not require insulin. Other individuals who have some residual insulin secretion but require exogenous insulin for adequate glycemic control can survive without it. Individuals with extensive β-cell destruction and therefore no residual insulin secretion require insulin for survival. The severity of the metabolic abnormality can progress, regress, or stay the same. Thus, the degree of hyperglycemia reflects the severity of the underlying metabolic process and its treatment more than the nature of the process itself.

  3. classification

  4. Diabetes can be classified into the following general categories: 1. Type 1 diabetes (due to autoimmune b-cell destruction, usually leading to ab- solute insulin deficiency, including latent autoimmune diabetes of adulthood) 2. Type 2 diabetes (due to a non-autoimmune progressive loss of adequate b-cell insulin secretion frequently on the background of insulin resistance and metabolic syndrome) 3. Specific types of diabetes due to other causes, e.g., monogenic diabetes syn- dromes (such as neonatal diabetes and maturity-onset diabetes of the young), diseases of the exocrine pancreas (such as cystic fibrosis and pancreatitis), and drug- or chemical-induced diabetes (such as with glucocorticoid use, in the treat- ment of HIV/AIDS, or after organ transplantation) 4. Gestational diabetes mellitus (diabetes diagnosed in the second or third tri- mester of pregnancy that was not clearly overt diabetes prior to gestation)

  5. SYMPTOMS 1- Classic symptoms of hyperglycemia include polyuria, polydipsia, nocturia, blurred vision and, infrequently, weight loss. These symptoms are often noted only in retrospect, after a blood glucose value has been shown to be elevated. Polyuria occurs when the serum glucose concentration rises significantly above 180 mg/dL (10 mmol/L), exceeding the renal threshold for glucose, which leads to increased urinary glucose excretion. Glycosuria causes osmotic diuresis (ie, polyuria) and hypovolemia, which in turn can lead to polydipsia. Patients who replete their volume losses with concentrated sugar drinks, such as non-diet sodas, exacerbate their hyperglycemia and osmotic diuresis. 2- Acute complication as - Diabetic ketoacidosis ( 20% of patients with type 1diabetes) - Rarely adults with type 2 diabetes can present with a hyperosmolar hyperglycemic state, characterized by marked hyperglycemia without ketoacidosis, severe dehydration, and obtundation. Diabetic ketoacidosis (DKA) as the presenting symptom of type 2 diabetes is also uncommon in adults but may occur under certain circumstances (usually severe infection or other illness) and in non-Caucasian ethnic groups. 3- Chronic complication Among patients with type 2 diabetes in the United Kingdom Prospective Diabetes Study, 25% had retinopathy; 9%, neuropathy; and 8%, nephropathy at the time of diagnosis. 4- Asymptomatic ;in older studies, the typical patient with type 2 diabetes had diabetes for at least 4-7 years at the time of diagnosis. 5- Atypical presentation ; Presentation of diabetes in elderly is less classical. Index of suspicion has to be high as patients usually do not develop glycosuria (increased renal threshold) and polydipsia (impaired thirst mechanism). They may present with non-specific features (failure to thrive, falls, dizziness, confusion, nocturia, etc) and Non Ketotic Hyperosmolar State (NKHS) . They may also present with infectious complications like malignant otitis externa, septicaemia, diabetic foot and complicated renal infections

  6. Diagnosis 1- Is the patients has diabetes ; - If there is any symptom or sign suggest DM Order for one or more the following tests to diagnose DM 1- HbA1C. FBS , RBS ,GTT 2- Other tests to be ordered as needed ( serum insulin , C-peptide , autoantibodies , HOMA-IR, genes ) Interpretation of the results ;

  7. Criteria for diagnosis

  8. advantage and disadvantage of test

  9. Which types of diabetes that patients has 1- Type 1 diabetes • Clinical supports ; a- Age ; usually young but may present in middle or old as (LADA) b- Family history ; less frequent c- Duration of illness , short d- Onset is progressive and may present with acute complication e- Body weight ; normal • - Laboratory support ; • a-Assessment of beta cell function ; Method used to assess beta cells function 1- Serum insulin level ; Disadvantage ; a- It has short half life b- 30% undergo hepatic clearance c- Its measurement is interfered with exogenous insulin by RIA 2- C-peptide - Plasma C-peptide - Urine creatinine to C-peptide ratio Advantages ; a- Long half life b- No hepatic clearance c- No interference with exogenous insulin 3- HOMA-B-cell

  10. B- presence of autoantibodies - types

  11. importance ; - diagnosis - subtype of type 1 ;

  12. - for staging

  13. 2-Type 2 diabetes • 1- Clinical supports • a- Age ; usually middle and old but may present in children and adult as (type 2 diabetes of youth ) • b- Family history ; more frequent • c- Duration of illness , long • d- Onset is slow progressive and may present with chronic complication • e- Body weight ; usually obese • - 2- Laboratory support ; • A- assessment of IR • B- Assessment of beta cell function ; 1- Serum insulin 2- Serum C-peptide level

  14. 3-Latent autoimmune diabetes of adult(LADA) ; 1- Clinical support a- Age ; usually 45-70 years b-Family history ; more frequent c - Duration of illness , long d- Onset is slow progressive and may present with chronic complication e- Body weight ; usually normal 2- Laboratory support ; a- Assessment of beta cell function ; 1- Serum insulin ; low 2- Serum C-peptide level ; low b-The presence of autoantibodies ; positive

  15. 4-Type 2 diabetes of youth 1- Clinical support ; a- Age ; 12-18 y b- Family history ; positive c- Onset ; slow , about is asymptomatic d- Duration ; long e- Over weight f- Ethenic variation g- Feature of insulin resistance ; as acanthosis negrecans , hypertension , POS , dyslipidemia h- History of GDM 2- Laboratory support ; • a- Assessment of beta cell function ; 1- Serum insulin ; normal 2- Serum C- peptide ; normal • b- No auto antibodies

  16. 5-Ketosis prone type 2 DM 1-Sudden in onset 2-No obesity 3-Positive FH 4-May present with DKA 5-Absence of markers of autoimmunity 6-No insulin resistance 7-There is decrease in first phase insulin secretion

  17. 6- MONOGENIC DIABETES A- neonatal B- MODY

  18. 7-Diagnosis of GDM

  19. TYPE 1 DM Defination ; Prevalence ; Pathogenesis ;

  20. Natural history

  21. Staging

  22. Subtype of type 1 1- Acute • 2- slowely progressive

  23. diagnosis A- clinical B- laboratory 1- Presence of autoantibodies importance 2- assessment of beta cell function

  24. Prevention

  25. treatment 1- treatment target • Blood glucose • - FBS • - RBS • - HbA1C • -

  26. treatment types • A- diet

  27. Treatment type 1- insulin • According to source • A - human insulin ; • - SHORT ACTING ; • - soluble • - intermediate acting • - NBH • - long acting • ultralente • B- insulin analogue • - rapid acting • - aspart • - lispro • - glargine

  28. long acting ; - glargine - detemer

  29. according to onset and duration

  30. who the pancreas secreate insulin • basal insulin secretion ( 1iu|hr ) its aim is to suppress glycogenolysis , lipolysis and proteolysis • Meal related insulin secretion as following ( 4 iu before breakfast , 3iu before lunch , 6 iu before dinner , 2 iu at bed time snack ) • PHASES OF INSULIN SECRETION • In nondiabetic individuals, approximately 50% of the total daily insulin is secreted during basal periods, suppressing lipolysis, proteolysis, and glycogenolysis. The remainder of insulin secretion is postprandial. In response to a meal, there is a rapid and sizable release of preformed insulin from storage granules within the beta cell. This "first phase" of insulin secretion promotes peripheral utilization of the prandial nutrient load, suppresses hepatic glucose production, and limits postprandial glucose elevation. First-phase insulin secretion begins within 2 minutes of nutrient ingestion and continues for 10 to 15 minutes. The second phase of prandial insulin secretion follows, and is sustained until normoglycemia is restored. • First-phase insulin secretion is often represented in clinical studies by the acute insulin response to an intravenous glucose bolus. While an intravenous glucose bolus is not equivalent to an oral mixed meal, it serves as a standardized beta-cell stimulus by which first-phase insulin secretion can be carefully compared among different subjects. Further, it demonstrates the sensitivity to and insulin response of the beta cell specifically to the glucose stimulus. It is this loss of beta-cell glucose sensitivity and responsiveness that declines early in the development of type 2 diabetes, even while responses to amino acid and other stimuli are preserved. • Evidence of impaired first-phase insulin release can be seen in the glucose tolerance test, demonstrated by a substantially elevated blood glucose level at 30 minutes, a marked drop by 60 minutes, and a steady climb back to baseline levels over the following hourly time points

  31. dose of insulin ; - dose of insulin 0.5-1 iu/kg / day Higher amount is required during - puberty - pregnancy - medical illness half of the total dose is given as basal insulin and half as prandial Method ; 1- multidose regimen ;

  32. drugs used in type 1 DM ; - Amylin analogues ; • Mechanism of action ; -

  33. Pramlintide is based on the naturally occurring b-cell peptide amylin and is approved for use in adults with type 1 diabetes. Clinical trials have demonstrated a modest reduction in A1C (0.3–0.4%) and modest weight loss (1 kg) with pramlintide 2- metformin 3- GLP1RA ; Liraglutide dose ; 1.8mg /day advantage ; - decrease HbA1C - decrease body weight - reduction in insulin dose 4- SGLT2I

  34. Type 2 DM Definition ; This form of diabetes, which accounts for ∼90–95% of those with diabetes, previously referred to as non-insulin-dependent diabetes, type II diabetes, or adultonset diabetes, encompasses individuals who have insulin resistance and usually have relative (rather than absolute) insulin deficiency At least initially, and often throughout their lifetime, these individuals do not need insulin treatment to survive Pathogenesis ; 1- Insulin resistance 2- Decreased insulin secretion by beta cells 3- Increased glucose production by liver 4- Incretin hormones deficiency and resistance 5- Increased renal tubular reabsorption of glucose 6- Hyperglucogenemia 7- Amylin deficiency 8- Rule of CNS

  35. 1- insulin resistance ; Defination ; Definition ; Insulin resistance (IR) is a physiological condition in which cells fail to respond to the normal actions of the hormone insulin. The body produces insulin, but the cells in the body become resistant to insulin and are unable to use it as effectively, leading to hyperglycemia. Beta cells in the pancreas subsequently increase their production of insulin, further contributing to hyperinsulinemia Causes ; rule of obesity in IR

  36. site of insulin resistance ‘Sites ; • a- Liver ; normally insulin suppress the hepatic glucose production , in case of insulin resistance the glucose production by liver is increased leadind to fasting hyperglycemia • b- skeletal muscle ; its important for oxidation and storage of glucose as glycogen in insulin resistance thereis defect in both uptake and storage of glucose ; which is due to ; • -defect in the upregulation of GLUT 4 • - Increased FFA flux to the skeletal muscle leads to inhibition of muscle glucose uptake ( Randle hypothesis ) , FFA inhibit muscle glucose utilization by inhibiting phosphofructokinase leading to increased muscle glucose with decreased uptake – • c- adipose tissue ; insulin resistance at adipose tissue leads to increased activity of enzyme lipoprotein lipase this leads to increase FFA production which in turn leads to • - Insulin resistance at liver • -Insulin resistance at skeletal muscle • - Deposition in beta cells of pancrease leads to decreased insulin secretion

  37. Sequale of IR

  38. 2-Beta cells dysfunction ; Causes ;

  39. 3-Incretin deficiency and resistance • Incretins are a group of gastrointestinal hormones that cause an increase in the amount • of insulin released from the beta cells of the islets of Langerhans after eating, before blood glucose levels become elevate d. They also slow the rate of absorption of nutrients into the blood stream by reducing gastric emptying and may directly reduce food intake. As expected, they also inhibit glucagon release from the alpha cells of the Islets of Langerhans. The two main candidate molecules that fulfill criteria for an incretin are glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide (also known as: glucose-dependent insulinotropic polypeptide or GIP). Both GLP-1 and GIP are rapidly inactivated by the enzyme dipeptidyl peptidase-4 (DPP-4). 

More Related